Clinical trials in Parkinson's disease (PD) patients have demonstrated that intraparenchymal AAV-mediated delivery of the GDNF analog neurturin to the putamen is safe and well-tolerated but have yet to meet a primary efficacy endpoint.87 Postmortem analysis has confirmed successful induction and sustained expression of neurturin. This evidence concerns the gene NRTN and Parkinson disease.